

Missed opportunities of flu vaccination in Italian target categories: insights from the online EPICOID 19 survey

Andrea Giacomelli^{*1}, Massimo Galli^{*1}, Stefania Maggi², Gabriele Pagani¹, Raffaele Antonelli Incalzi³, Claudio Pedone³, Mauro di Bari⁴, Marianna Noale², Caterina Trevisan^{2,5}, Fabrizio Bianchi⁶, Marcello Tavio⁷, Massimo Andreoni⁸, Claudio Mastroianni⁹, Aleksandra Sojic¹⁰, Federica Prinelli¹⁰ and Fulvio Adorni¹⁰ on Behalf of EPICOID19 Working Group.

¹Infectious Diseases Unit, Department of Biomedical and Clinical Sciences L.Sacco, Università di Milano, ASST Fatebenefratelli Sacco, Milan, Italy Via G.B. Grassi 74, 20157 Milano, Italy; andrea.giacomelli@unimi.it; massimo.galli@unimi.it; gabriele.pagani@unimi.it

²National Research Council, Institute of Neuroscience, Aging branch, Via Vincenzo Maria Gallucci 16, 35128 Padova; stefania.maggi@in.cnr.it; caterina.trevisan.5@studenti.unipd.it; marianna.noale@in.cnr.it

³Unit of Geriatrics, Department of Medicine, Biomedical Campus of Rome, via Alvaro del Portillo, 21, 00128 Rome, Italy; r.antonelli@unicampus.it; claudio.pedone@gmail.com

⁴Geriatric Intensive Care Medicine, University of Florence and Azienda Ospedaliero-Universitaria Careggi, Viale Peraccini 18, 50139 Florence, Italy; mauro.dibari@unifi.it

⁵Geriatric Unit, Department of Medicine (DIMED), University of Padova, Via Giustiniani 2, 35128 Padova, Italy; caterina.trevisan.5@studenti.unipd.it

⁶ National Research Council, Institute of Clinical Physiology, Via G. Moruzzi 1, 56124 Pisa (PI), Italy; fabrieipi@ifc.cnr.it

⁷Division of Infectious Diseases, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy; marcello.tavio@ospedaliriuniti.marche.it

⁸Infectious Diseases Clinic, Department of System Medicine, Tor Vergata University of Rome, 00133 Rome, Italy; andreoni@uniroma2.it

⁹Public Health and Infectious Disease Department, "Sapienza" University, Rome, Italy; claudio.mastroianni@uniroma1.it

¹⁰National Research Council, Institute of Biomedical Technologies, Via Fratelli Cervi 93, 20090 Segrate (MI), Italy; aleksandra.sojic@itb.cnr.it; federica.prinelli@itb.cnr.it; fulvio.adorni@itb.cnr.it;

*The authors contributed equally to the manuscript

39

40

41 Corresponding author:

42 Andrea Giacomelli, MD

43 Luigi Sacco DIBIC, University of Milan,

44 III Infectious Diseases Unit, L. Sacco Hospital,

45 Via G.B. Grassi 74,

46 20157 Milano,

47 Italy

48 Tel. +39.02.50319761; Fax +39.02.50319758; E-mail andrea.giacomelli@unimi.it

49 ORCID ID: 0000-0003-3685-4289

50

51

52

53 **Abstract:** We aimed to assess the reported rate of flu vaccination in the season 2019/2020 in
 54 respondents to the Italian nationwide online EPICOVID 19 survey. A national convenience sample
 55 of volunteers aged 18 or older was assessed between 13th April and 2nd June 2020. Flu vaccine rates
 56 were calculated for all classes of age. The association between the independent variables and the flu
 57 vaccine was assessed by applying a multivariable binary logistic regression model. Of the 198,822
 58 respondents 41,818 (21.0%) reported to have received a flu vaccination shot during the last
 59 influenza season. In particular, 15,009 (53.4%) subjects aged 65 years or older received a flu
 60 vaccination shot. Being 65 years aged or older (aOR 3.06, 95%CI 2.92-3.20) and having a high
 61 education level (aOR 1.34, 95%CI 1.28-1.41) were independently associated to flu vaccination. Heart
 62 and lung diseases were the morbidities associated with the higher odds of being vaccinated [aOR
 63 1.97 (95%CI 1.86-2.09) and aOR 1.92 (95%CI 1.84-2.01), respectively]. Nursing home residents aged
 64 ≥ 65 years showed a lower odds of being vaccinated [aOR 0.39 (95%CI 0.28-0.54)]. Our data claims
 65 for an urgent public health effort to fill the gap of missed vaccination opportunities reported in the
 66 past flu seasons.

67

68 **Keywords:** SARS-CoV-2, COVID-19, influenza, vaccine, elderly, Italy

69

70

71

72

73

74

75

76 1. Introduction

77 Influenza is an acute viral infection of the respiratory tract, whose clinical manifestations range from
78 mild upper respiratory tract symptoms to life treating complications requiring hospitalization. It is
79 estimated that every year flu can cause worldwide high morbidity and mortality epidemics with
80 approximately 3 to 5 million cases and between 250,000 and 500,000 deaths [1]. In the northern
81 hemisphere Influenza viruses circulating during fall and winter seasons cause epidemic outbreaks
82 with an important burden of morbidity and a remarkable mortality rate. In Italy, the cost for the
83 national health care system has been estimated an average of 1.4 US\$ billion for each season between
84 1999 and 2008 [2].

85 The new pandemic caused by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) has
86 rapidly spread starting from China in late December 2019 and abruptly involving the north of Italy
87 in late February 2020 [3]. SARS-CoV-2 infection is able to cause a severe respiratory syndrome with
88 the requirement of intensive care assistance and eventually leading to death in a significant
89 percentage of hospitalized patients [4, 5]. The dramatic impact of the SARS-CoV-2 pandemic on the
90 Italian national healthcare system lead the national authorities to impose a national lock-down from
91 March 9 to May 18, 2020. After a period of apparent control in summer months, current Italian
92 epidemiological situation is evolving with a slight daily increment of the number of cases and a
93 progressive increment of hospitalized patients [6]. Consequently, non-pharmacological
94 interventions, such as the face mask combined with social distancing, are still enforced.

95 The new challenge in the management of the pandemic will appear in the 2020/2021 flu season,
96 when the co-occurrence of influenza and flu-like illnesses may overcome the diagnostic capacity of
97 our system with regard to the capability for molecularly testing all subjects with respiratory
98 symptoms. Moreover, the clinical impact of subsequent or concomitant influenza and SARS-CoV-2
99 infections is still unknown, especially in the elderly populations and in patients with comorbidities.

100 To date, no effective treatment has been demonstrated to radically change the natural history of
101 SARS-CoV-2 infection [7] and several vaccination strategies are still under development [8]; on the
102 other hand, flu vaccination is able to decrease both the incidence rates of influenza and to moderate
103 the severity of the disease in case of infection. Moreover, a remarkable decrease in morbidity for
104 pneumonia, respiratory and cardiovascular complications and consequent risk of hospitalization
105 and death has been consistently reported in the literature [9-12]. The reduced risk of hospitalization
106 is particularly important considering the significant amount of hospital resources that are required
107 for the management of COVID 19 patients which required hospitalization and intensive care
108 assistance in a not negligible percentage [4, 5]. In the end, influenza vaccinations are not only safe,
109 with few adverse events related to its administration, but also proven to be effective in children
110 above 6 months of age, people with comorbid conditions and also in the elderly population [9, 10,
111 13].

112 Despite national and international recommendations for routine flu vaccination, vaccine uptake in
113 Italy remains low in the general population, as well as in the high risk groups. Our aim was to
114 assess the reported rate of flu vaccination in the season 2019/2020 in respondents to the nationwide
115 online EPICOVID 19 survey [14] and to identify factors associated with the uptake of flu vaccination,
116 in order to address potential gaps to be filled in the public health system.

117 2. Materials and Methods

118 2.1 Study design and setting

The study design was described elsewhere [14, 15] and the study was registered (ClinicalTrials.gov NCT04471701). In brief, EPICOVID19 is an Italian cross-sectional, web-based survey that was initiated in April 2020. A national convenience sample of volunteers aged 18 or older with access to internet and able to give an informed consent was assessed. The participants were recruited via social media (Facebook, Twitter, Instagram, Whatsapp), press releases, internet pages, local radio, TV stations, and institutional websites; the European Commission's open-source official EUSurvey management tool was used to collect the data (<https://epicovid19.itb.cnr.it/>). The geographical coverage [14] such as the representativeness of the survey according to the Italian official demographic data [15] were described elsewhere.

2.2 Data collection and variables

For the purposes of this study, we analysed all the survey responses collected between 13th April and 2nd June 2020. The socio-demographic information included sex (male vs female, furtherly classified as pregnant or not), age (18-24, 25-29 up to 90+ and further categorized as <65 or ≥ 65 years of age), educational level (primary school or less = Low, middle or high school = Medium, and university degree or post-graduate = High), and occupational status (unemployed, employed, retired, student, and other). Work categories included in the national guidelines for flu vaccine were generated (Health professionals, armed forces, agricultural, forestry and fisher workers). Two ad hoc dummy variables were also created for categorizing residents in nursing homes (yes or not) and for respondents living with an “at risk cohabitant” according to the 2017-2019 Italian national vaccination plan (yes or not) [16]. Chronic conditions reported were lung diseases, heart diseases, metabolic disorders, renal diseases, oncological diseases, diseases of the immune system, liver diseases and pre-planned major surgical procedures. A new variable was created by summing the chronic conditions referred by participants (categorised as none, 1, 2 or ≥3 co-morbidities). Information about autonomy in carrying out daily activities, self-rated health (very bad, bad, adequate, good or very good) was also available. The participants were also asked if they had received an influenza vaccination during the previous autumn/winter season.

2.3 Study population and group definition

Out of the 207,341 respondents, the study population consisted of 198,822 participants who provided informed consent, and for whom the data were fully available for the analysis. For the aim of this study, participants were categorized as vaccinated or not vaccinated for flu during the 2019/2020 season.

2.4 Statistical analysis

Descriptive analyses were performed to show the numerical distributions, overall and by flu vaccine status, of all the variables that at a later stage were included as independent in the models applied for statistical inference. Continuous variables were expressed as mean [Standard Deviation (SD)] whereas categorical and ordinal ones as count and percentages. Flu vaccine rates were calculated for all classes of age and for all Italian regions, in this latter case also stratifying by sex (male vs female) and age (<65 vs ≥65 years). The association between the independent variables and the flu vaccine (0=not reported, 1=reported) was assessed by applying a multivariable binary logistic regression model. Adjusted Odds Ratios (aOR), together with their 95% Confidence Intervals (CI), were estimated for each independent variable, with p-level of statistical significance set at .05, two tails. The same regression model was used when restricting the population analysed to older people (≥65 years). All the statistical analyses were carried out using SPSS version 25 (IBM Corp) and STATA version 15.0 (StataCorp LP).

2.5 Ethics and consent to participate

The Ethics Committee of the National Institute for Infectious Diseases (Italian: Istituto Nazionale per le Malattie Infettive I.R.C.C.S. Lazzaro Spallanzani) approved the EPICOV19 study protocol (Protocol No. 70, 12/4/2020). The participants were requested to give their informed consent when they first accessed the on-line platform. The study was carried out in accordance with the principles of the Declaration of Helsinki.

All data were handled and stored in accordance with the European Union General Data Protection Regulation (EU GDPR) 2016/679; data transfer included encrypting/decrypting and password protection.

3. Results

Between April and June 2020 198,822 participants filled the online EPICOV19 survey and 41,818 (21.0%) reported to have received a flu vaccination shot during the last influenza season (2019/2020). Respondents were prevalently females (59.7%) and aged between 18-64 years (85.9%) with a mean age of 48 (SD +/- 14.7 years) (Table 1).

177

		Flu shot during 2019/2020 flu season		
		No	Yes	Total
		N=157004	N=41818 (21.0)	N=198822
		(79.0)		(100)
Sex at birth	Females	95402 (80.4)	23255 (19.6)	118657 (59.7)
	Males	61602 (76.8)	18563 (23.2)	80165 (40.3)
Class of age	<65 years	143921 (84.3)	26809 (15.7)	170730 (85.9)
	65+ years	13083 (46.6)	15009 (53.4)	28092 (14.1)
Age		45.9 ± 13.6	55.8 ± 15.9	48.0 ± 14.7
Educational level	Low	8662 (73.1)	3192 (26.9)	11854 (6.0)
	Middle	56058 (81.5)	12742 (18.5)	68800 (34.6)
	High	92284 (78.1)	25884 (21.9)	118168 (59.4)
Employment status	Employed	114488 (83.7)	22368 (16.3)	136856 (68.8)
	Student	11781 (87.7)	1655 (12.3)	13436 (6.8)
	Unemployed	8064 (87.8)	1120 (12.2)	9184 (4.6)
	Retired	14056 (49.7)	14252 (50.3)	28308 (14.2)
	Other	8615 (78.0)	2423 (22.0)	11038 (5.6)
Morbidities or clinical conditions	Lung diseases	7497 (65.4)	3959 (34.6)	11456 (5.8)
	Heart disease	2996 (47.5)	3318 (52.5)	6314 (3.2)
	Metabolic disorders	5662 (60.7)	3663 (39.3)	9325 (4.7)
	Renal diseases	1044 (61.8)	644 (38.2)	1688 (0.8)
	Oncological diseases	3809 (60.0)	2541 (40.0)	6350 (3.2)
	Diseases of the immune system	12998 (74.2)	4516 (25.8)	17514 (8.8)
	Liver diseases	999 (67.2)	488 (32.8)	1487 (0.7)
	Surgical procedures	5499 (72.3)	2103 (27.7)	7602 (3.8)
Number of morbidities	None	123240 (82.6)	25928 (17.4)	149168 (75.0)
	One	28077 (70.6)	11689 (29.4)	39766 (20.0)
	Two	4782 (59.2)	3297 (40.8)	8079 (4.1)

Work categories recommended for flu vaccine	Three or more	905 (50.0)	904 (50.0)	1809 (0.9)
	Health professionals	9474 (64.3)	5262 (35.7)	14736 (7.4)
	Armed forces	1610 (79.8)	407 (20.2)	2017 (1.0)
	Agricultural, forestry and fishery workers	674 (82.3)	145 (17.7)	819 (0.4)
Other conditions for recommending flu vaccine	Pregnancy	2446 (76.7)	743 (23.3)	3189 (1.6)
	Residents in nursing home	129 (39.0)	202 (61.0)	331 (0.2)
	Cohabitants at risk	26883 (70.5)	11225 (29.5)	38108 (19.2)
	Not self-sufficient in carrying out daily activities	425 (46.0)	499 (54.0)	924 (0.5)
Self-perceived health status	Good	135325 (80.9)	31942 (19.1)	167267 (84.1)
	Adequate	20585 (69.2)	9159 (30.8)	29744 (15.0)
	Bad	1094 (60.4)	717 (39.6)	1811 (0.9)

Table 1: characteristics of study participants according to being or not vaccinated for influenza in the 2019/2020 flu season.

180

Vaccination coverage progressively increased with age, from 11% between 18 and 24 years of age and peaking to 72.9% between 85 and 89 years of age (Supplementary Table 1).

Class of age	Flu shot during 2019/2020 flu season		
	No	Yes	Total
	N=157004 (79.0)	N=41818 (21.0)	N=198822 (100)
18-24	8916 (89.0)	1099 (11.0)	10015 (5.0)
25-29	12965 (87.6)	1839 (12.4)	14804 (7.4)
30-34	15539 (87.1)	2311 (12.9)	17850 (9.0)
35-39	17049 (85.6)	2864 (14.4)	19913 (10.0)
40-44	17260 (85.0)	3036 (15.0)	20296 (10.2)
45-49	19391 (86.4)	3055 (13.6)	22446 (11.3)
50-54	19848 (86.0)	3235 (14.0)	23083 (11.6)
55-59	18753 (81.7)	4195 (18.3)	22948 (11.5)
60-64	14200 (73.3)	5175 (26.7)	19375 (9.7)
65-69	7885 (55.3)	6373 (44.7)	14258 (7.2)
70-74	3504 (41.1)	5018 (58.9)	8522 (4.3)
75-79	1081 (35.1)	2003 (64.9)	3084 (1.6)
80-84	379 (27.5)	998 (72.5)	1377 (0.7)
85-89	136 (27.0)	367 (73.0)	503 (0.3)
90+	98 (28.2)	250 (71.8)	348 (0.2)

Supplementary Table 1. Vaccination coverage in participants according to the class of age.

184

Vaccination coverage ranged widely across Italian regions, from 18.2% in Abruzzo to 23.7% in Friuli-Venezia Giulia in the overall respondents (Figure 1A) and from 48.7% in Piemonte to 63.6% Friuli-Venezia Giulia in those aged ≥ 65 years (Figure 1B).



Figure 1. A, vaccination coverage according to the different Italian region in respondents aged ≥ 18 years. B, vaccination coverage according to the different Italian regions in respondents aged ≥ 65 years.

3.1 Multivariable model of factors associated to flu vaccination

Figure 2 shows the multivariable model for subjects aged 18 years or older.




Figure 2. Multivariable model of factors associated to flu vaccination in the 2019/2020 season in respondents aged ≥ 18 years.

The multivariable model stratified by age (18-64 years and ≥ 65 years) are reported in Table 2. When considering the whole respondents, being 65 years or older (aOR 3.06, 95%CI 2.92-3.20) and having a high education level (aOR 1.34, 95%CI 1.28-1.41) were independently associated to flu vaccination. Conversely, those unemployed showed a reduced odds of being vaccinated (aOR 0.80, 95%CI 0.75-0.85).

	Age 18-64 years N=26.809/170.730 (15.7)		Age ≥ 65 years N=15.009/28.092	
	aOR (95%CI)	p	aOR (95%CI)	p
Sex and pregnancy				
Males	1		1	
Not pregnant females	0.83 (0.81 to 0.85)	.000	1.19 (1.13 to 1.25)	.000
Pregnant females	1.68 (1.54 to 1.85)	.000		
Age, per 10 years more	1.24 (1.22 to 1.26)	.000	2.01 (1.90 to 2.12)	.000
Educational level				
Low	1		1	
Middle	1.08 (1.01 to 1.16)	.034	1.06 (0.98 to 1.14)	.134
High	1.59 (1.49 to 1.71)	.000	1.40 (1.29 to 1.51)	.000
Employment status				
Employed	1		1	
Student	1.50 (1.40 to 1.59)	.000	-	
Unemployed	0.88 (0.82 to 0.94)	.000	1.11 (0.80 to 1.53)	.532
Retired	1.65 (1.54 to 1.76)	.000	1.52 (1.40 to 1.64)	.000
Other	1.09 (1.02 to 1.15)	.006	1.24 (1.10 to 1.40)	.001
Morbidities or clinical conditions				
Lung diseases	1.95 (1.85 to 2.05)	.000	1.91 (1.73 to 2.10)	.000
Heart disease	2.15 (1.98 to 2.33)	.000	1.54 (1.42 to 1.66)	.000
Metabolic disorders	1.68 (1.58 to 1.78)	.000	1.33 (1.23 to 1.43)	.000
Renal diseases	1.41 (1.22 to 1.63)	.000	1.10 (0.91 to 1.30)	.305
Oncological diseases	1.62 (1.50 to 1.75)	.000	1.16 (1.06 to 1.26)	.001
Diseases of the immune system	1.17 (1.12 to 1.23)	.000	1.02 (0.94 to 1.10)	.583
Liver diseases	1.00 (0.85 to 1.18)	.972	0.92 (0.76 to 1.10)	.410
Surgical procedures	1.06 (0.99 to 1.14)	.093	1.13 (1.02 to 1.24)	.021
Work categories recommended for flu vaccine				
Not recommended	1		1	
Agricultural, forestry and fishery workers	0.79 (0.62 to 1.00)	.047	0.97 (0.66 to 1.42)	.895
Armed forces	0.97 (0.85 to 1.12)	.699	1.24 (0.93 to 1.65)	.139
Health professionals	2.99 (2.87 to 3.11)	.000	1.54 (1.36 to 1.73)	.000
Other conditions for recommending flu vaccine				
Residents in nursing home	7.20 (4.29 to 12.10)	.000	0.39 (0.28 to 0.54)	.000
Presence of persons at risk in the household	1.36 (1.31 to 1.40)	.000	1.42 (1.35 to 1.49)	.000
Not self-sufficient in carrying out daily activities	1.83 (1.41 to 2.38)	.000	0.54 (0.43 to 0.66)	.000
Self-perceived health status				
Good	1		1	
Adequate	1.15 (1.10 to 1.19)	.000	1.16 (1.10 to 1.22)	.000

Bad 1.24 (1.08 to 1.42) .002 1.36 (1.12 to 1.62) .002

Table 2. Multivariable binary logistic regression analysis on the probability of being or not vaccinated during the 2019/2020 flu season according to being 18-64 years old or ≥ 65 years old.

Among comorbidities, heart and lung diseases were conditions associated with higher odds of being vaccinated, both in subjects aged 18-64 [aOR 2.15 (1.98 to 2.33) and aOR 1.95 (1.85 to 2.05), respectively] and in those aged above 65 years [aOR 1.54 (95%CI 1.42-1.67) and aOR 1.91 (95%CI 1.73-2.12), respectively]. The odds of being vaccinated progressively increased with the number of reported morbidities, with a more pronounced effect in those aged below 65 years (Supplementary Table 3).

	Age 18-64 years		Age ≥ 65 years	
	N=26.809/170.730 (15.7)		N=15.009/28.092 (53.4)	
	aOR (95%CI)	p	aOR (95%CI)	p
Number of morbidities				
None	1		1	
One	1.54 (1.49 to 1.59)	.000	1.43 (1.35 to 1.51)	.000
Two	2.18 (2.05 to 2.33)	.000	1.70 (1.55 to 1.86)	.000
Three or more	2.60 (2.26 to 2.99)	.000	1.66 (1.42 to 1.94)	.000

Supplementary Table 3. Multivariable binary logistic regression analysis on the probability of being or not vaccinated during the 2019/2020 flu season according to the number of reported morbidities.

Health care workers showed a higher odds of being vaccinated [aOR 2.79 (95%CI 2.68-2.90)] when compared to work position without vaccine recommendation.

Living in a nursing home and being unable to perform daily activities were both associated with a lower odds of being vaccinated in those aged 65 years or older [aOR 0.39 (95%CI 0.28-0.54) and aOR 0.54 (95%CI 0.43-0.69), respectively].

4. Discussion

The EPICOVID 19 web based survey, which aimed to highlight different epidemiological and clinical aspects of COVID-19 epidemic in the first wave of the Italian epidemic, allowed the assessment of flu vaccination coverage in the 2019/2020 flu season in a large unselected sample of respondents. Moreover, we were able to identify predictors of flu vaccine uptake and highlight significant gaps in vaccination coverage in key populations such as in those residing in nursing homes and in those reporting specific medical conditions (i.e. liver diseases, kidney diseases and diseases of the immune system).

Our findings showed an overall vaccination rate of 21% and a rate of 53.4% in those aged 65 years or older, clearly below the target recommended coverage. The available National data obtained from a surveillance system collecting data from the general practitioners since 1990/2000 flu season, report a progressive increase in the vaccination coverage until 2009/2010 for the overall population (19.6 per 100 inhabitants) and until 2008/2009 for those aged 65 years or older (66.3 per 100 inhabitants). A progressive decline was subsequently observed for those aged 65 years or older until 2014/2015 (48.5 per 100 inhabitants) followed by a slight progressive increase in the subsequent years [17]. According to the official data of the Italian Ministry of Health of vaccination coverage in 2019/2020 flu season the overall vaccination coverage in the whole Italian population was 16.7 over 100 inhabitants and 54.6 over 100 inhabitants in those aged 65 years or older confirming the trend

toward an increasing vaccination coverage [18]. Our data can not to be applied to the general estimates due to the absence in the survey of subjects aged 17 or younger. Whereas, the vaccination coverage observed in those aged 65 years or older appeared to be quite comparable to that reported by the official estimates (53.4% *vs* 54.6%, respectively). Although slightly increasing in recent years, the percentage observed in our study is lower than the target coverage of 75% in those aged 65 years or older. These data are particularly worrisome, because in the current fall/winter season in the northern hemisphere, with the concomitant co-circulation of both influenza and SARS-CoV-2 viruses, we will face a major challenge due to diagnostic and clinical problems in the presence of upper and lower respiratory tract symptoms [19]. Based on these concerns, for the 2020/2021 flu season the Italian ministry of Health recommends extending the vaccination coverage to the whole population, free of charge also for subject aged between 60 and 64 years [20]. If the free-of-charge administration of the influenza vaccine in this age-group will improve the uptake is to be demonstrated, but it will help to quantify the impact of the economical barrier to vaccination.

Recent findings support the need to increase the vaccination coverage, considering, on top of the well-known health and economic advantages, also the observed association between flu vaccination and reduction in SARS-CoV-2 nasopharyngeal swab positivity [15] and lower COVID-19 severity and mortality [21-23]. Therefore, the impact of vaccinations should be assessed not only based on their ability to prevent the related infections, but also on their broader impact on other communicable and not-communicable diseases occurring concurrently in the target population.

Our findings highlight a worrisome low vaccination coverage in subjects aged between 60-64 years and 65-69 years (26.7% and 44.7%, respectively). The low vaccination coverage in this group could be partially explained by a self-perception of wellbeing and low risk perception [24]. Nevertheless, these age groups are at high risk of COVID-19 complications and mortality, as observed in the Italian COVID-19 patients, therefore strategies to overcome their hesitancy towards vaccines and to increase vaccine accessibility and uptake are of paramount relevance [4, 25].

Another interesting finding observed is that people with higher education level seems to be better predisposed to vaccination when compared to the low socio-economic level. If on the one hand, low education level is a known general barrier to vaccines [26] on the other, our sample of generally higher educational level compared to the general population, reported overall a low uptake, meaning that multiple factors, beyond health literacy and access to health care services, need to be addressed. Moreover, the finding of a higher coverage among those with comorbidities suggest an attitude to consider the vaccination as a relevant intervention mainly for individuals at high risk, and not as a meaningful intervention for health promotion [27].

Our results showed that patients with heart and lung diseases seem to have a higher odds of being vaccinated when compared to those with other comorbidities, in particular kidney and liver disease. These findings raise particular concern, because it is clearly demonstrated that patients with chronic conditions, not only cardiovascular or respiratory diseases, are at higher risk of many vaccine-preventable diseases, including influenza, that increase the risk of serious complications, hospitalization, and death. Moreover, vaccine preventable diseases are more difficult to manage, because of increased risk of drug interactions and potential adverse effects [27].

In our study, flu vaccination resulted positively associated with being a health care worker, compared to other work-categories. Nevertheless, an extremely low percentage of health care workers respondents accounting for 35.7% received a flu shot in the last season. Although the percentage reported in our study is surprisingly higher compared to that reported in the literature in Italian health care workers, ranging from 14% [28] to 16% [29], it underlines the need for urgent measures to increase vaccination coverage in Italian health care workers. Vaccination of health care workers against influenza is a key component of infection control, and the rationale for it is based on the need to protect the health care workers and their high-risk patients in nursing homes, hospitals,

and outpatient clinics. Moreover, in time of extreme demand, reducing the absenteeism due to influenza and its complications, contributes to the preservation of the essential health care services.

The finding that nursing home residents aged 65 years or older have a 61% higher odds of not being vaccinated compared to the rest of the population was unexpected and definitively worrisome. These subjects have high rates of underlying medical conditions and, therefore, are at higher risk of infectious disease outbreaks. As we have learned during the recent pandemic, about half of deaths due to COVID-19 were among nursing homes residents, underlying a critical health disparity that need to be addressed urgently. Increased vaccination rates and increased testing for preventable infectious disease of residents and staff, and increased access to personal protective measures and equipment are mandatory in all nursing homes, in order to protect this vulnerable subgroup of our population [30–32].

4.1 Strengths and limitations

The main strength of our research was the possibility to assess factors associated with flu vaccination in a large unselected group of respondents to an online survey. In fact, Italian estimates on past flu vaccination seasons reported aggregated data for the general population and for those aged 65 years or older but failed to address among the target group which are categories with significant barriers to achieve the pre-planned goal for flu vaccine coverage.

Our study has several limitations. First, the absence of subjects aged below 18 years makes impossible the comparison of our data with that of the Italian general population reported by the ministry of health. Second, the high percentage of high education and health care workers observed in our sample should be considered in the interpretation of the results for the possible impact on behaviours and opportunities toward a better health. Third, caution is warranted in the interpretation of flu vaccination coverage of nursing home residents due to the possibility of recalling bias. In the end, the sample cannot be considered fully representative of the Italian demographic curve and consequently our findings could be not completely generalizable to the Italian population.

5. Conclusions

Our data confirm a low vaccination coverage in the overall respondents to the online EPICOV19 survey and in particular, far below the national recommendations in target populations, such as those 65 years or older, in subjects at high risk due to chronic conditions and in health care workers. In the perspective of the next fall winter season, with the probable co-circulation of influenza and SARS-CoV-2 in the norther hemisphere, the population will remain vulnerable to concurrent epidemics. The morbidity and mortality impact will be directly related to the strength of the public health response, which must be based on effective infection prevention tools currently available: the non-pharmacologic interventions (i.e. social distance and face masks) and the widespread implementation of influenza vaccination to fill the gap of missed vaccination opportunities reported in the past flu seasons.

Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1,

Supplementary Table 1. Vaccination coverage in participants according to the class of age.

Supplementary Table 2. Vaccination coverage per class of age according to the Italian official national data for the 2019/2020 flu season and in the EPICOV19 respondents.

Supplementary Table 3. Multivariable binary logistic regression analysis on the probability of being or not vaccinated during the 2019/2020 flu season according to the number of reported morbidities.

Author Contributions: Conceptualization, A.G., M.G., S.M., F.P., F.A.; Formal analysis, F.P., F.A.; Methodology, A.G., M.G., S.M., F.P. and F.A.; Project administration, F.A.; Supervision, M.G. and F.A.; Writing—original draft, A.G., M.G., F.P., S.M. and F.A.; Writing—review & editing, S.M., M.N., C.T., R. A.I., G.P., G.B., M.D.B., A.S., M.T., C.M., M.A., F.P., F.A. The corresponding author, A.G., attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding

Acknowledgments: The EPICoVID19 Working Group: Fulvio Adorni (National Research Council, Institute of Biomedical Technologies, Via Fratelli Cervi 93, 20090 Segrate (MI), Italy); Federica Prinelli (National Research Council, Institute of Biomedical Technologies, Via Fratelli Cervi 93, 20090 Segrate (MI), Italy); Fabrizio Bianchi (National Research Council, Institute of Clinical Physiology, Via G. Moruzzi 1, 56124 Pisa (PI), Italy); Andrea Giacomelli (Infectious Diseases Unit, Department of Biomedical and Clinical Sciences L.Sacco, Università di Milano, ASST Fatebenefratelli Sacco, Milan, Italy Via G.B. Grassi 74, 20157 Milano, Italy); Gabriele Pagni (Infectious Diseases Unit, Department of Biomedical and Clinical Sciences L.Sacco, Università di Milano, ASST Fatebenefratelli Sacco, Milan, Italy Via G.B. Grassi 74, 20157 Milano, Italy); Dario Bernacchia (Infectious Diseases Unit, Department of Biomedical and Clinical Sciences L.Sacco, Università di Milano, ASST Fatebenefratelli Sacco, Milan, Italy Via G.B. Grassi 74, 20157 Milano, Italy); Stefano Rusconi (Infectious Diseases Unit, Department of Biomedical and Clinical Sciences L.Sacco, Università di Milano, ASST Fatebenefratelli Sacco, Milan, Italy Via G.B. Grassi 74, 20157 Milano, Italy); Stefania Maggi (National Research Council, Neuroscience Institute, Aging branch, Via Vincenzo Maria Gallucci 16, 35128 Padova, Italy); Caterina Trevisan (University of Padova, Department of Medicine (DIMED) – Geriatric Unit, Via Giustiniani 2, 35128 Padova (PD), Italy); National Research Council, Neuroscience Institute, Via Giustiniani 2, 35128 Padova (PD), Italy); Marianna Noale (National Research Council, Neuroscience Institute, Aging branch, Via Vincenzo Maria Gallucci 16, 35128 Padova, Italy); Sabrina Molinaro (National Research Council, Institute of Clinical Physiology, Via G. Moruzzi 1, 56124 Pisa (PI), Italy); Luca Bastiani (National Research Council, Institute of Clinical Physiology, Via G. Moruzzi 1, 56124 Pisa (PI), Italy); Loredana Fortunato (National Research Council, Institute of Clinical Physiology, Via G. Moruzzi 1, 56124 Pisa (PI), Italy); Nithiya Jesuthasan (National Research Council, Institute of Biomedical Technologies, Via Fratelli Cervi 93, 20090 Segrate (MI), Italy); Aleksandra Sojic (National Research Council, Institute of Biomedical Technologies, Via Fratelli Cervi 93, 20090 Segrate (MI), Italy); Carla Pettenati (National Research Council, Institute of Biomedical Technologies, Via Fratelli Cervi 93, 20090 Segrate (MI), Italy); Marcello Tavio (Division of Infectious Diseases, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy); Massimo Andreoni (Infectious Diseases Clinic, Department of System Medicine, Tor Vergata University of Rome, 00133 Rome, Italy); Claudio Mastroianni (Public Health and Infectious Disease Department, "Sapienza" University, Rome, Italy); Raffaele Antonelli Incalzi (Unit of Geriatrics, Department of Medicine, Biomedical Campus of Rome, via Alvaro del Portillo, 21, 00128 Rome, Italy); Massimo Galli (Infectious Diseases Unit, Department of Biomedical and Clinical Sciences L.Sacco, Università di Milano, ASST Fatebenefratelli Sacco, Milan, Italy Via G.B. Grassi 74, 20157 Milano, Italy).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. http://www.who.int/influenza/gisrs_laboratory/en/ accessed 23/09/2020
2. Lai PL, Panatto D, Ansaldi F et al. Burden of the 1999–2008 seasonal influenza epidemics in Italy: comparison with the H1N1v (A/California/07/09) pandemic. *Hum Vaccin*. 2011 Jan-Feb;7 Suppl:217–25.
3. Zehender G, Lai A, Bergna A, et al. Genomic characterization and phylogenetic analysis of SARS-CoV-2 in Italy [published online ahead of print, 2020 Mar 29]. *J Med Virol*. 2020;10.1002/jmv.25794.
4. Giacomelli A, Ridolfo AL, Milazzo L, et al. 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study. *Pharmacol Res*. 2020;158:104931.
5. Grasselli G, Zangrillo A, Zanella A, et al; COVID-19 Lombardy ICU Network. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA*. 2020 Apr 28;323(16):1574–1581.


- 403 6. <https://www.epicentro.iss.it/en/coronavirus/sars-cov-2-dashboard> accessed 23/09/2020
- 404 7. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and
405 network meta-analysis. *BMJ*. 2020;370:m2980. Published 2020 Jul 30. doi:10.1136/bmj.m2980
- 406 8. Bar-Zeev N, Inglesby T. COVID-19 vaccines: early success and remaining challenges. *Lancet*. 2020 Sep
407 3:S0140-6736(20)31867-5. doi: 10.1016/S0140-6736(20)31867-5.
- 408 9. Demicheli V, Jefferson T, Di Pietrantonj C, et al. Vaccines for preventing influenza in the elderly. *Cochrane*
409 *Database Syst Rev*. 2018;2(2):CD004876.
- 410 10. Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy
411 children. *Cochrane Database Syst Rev*. 2018;2(2):CD004879. Published 2018 Feb 1.
412 doi:10.1002/14651858.CD004879.pub5
- 413 11. Demicheli V, Jefferson T, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in
414 healthy adults. *Cochrane Database Syst Rev*. 2018;2(2):CD001269.
- 415 12. Demurtas J, Celotto S, Beaudart C, et al. The efficacy and safety of influenza vaccination in older people:
416 An umbrella review of evidence from meta-analyses of both observational and randomized controlled
417 studies. *Ageing Res Rev*. 2020;62:101118.
- 418 13. Bonanni P, Boccalini S, Zanobini P, et al. The appropriateness of the use of influenza vaccines:
419 Recommendations from the latest seasons in Italy. *Hum Vaccin Immunother*. 2018 Mar 4;14(3):699-705.
- 420 14. Adorni F, Prinelli F, Bianchi F, et al. Self-reported symptoms of SARS-CoV-2 infection in a
421 non-hospitalized population: results from the large Italian web-based EPICOV19 cross-sectional survey
422 [published online ahead of print, 2020 Jul 10]. *JMIR Public Health Surveill*. 2020;10.2196/21866.
- 423 15. Noale M, Trevisan C, Maggi S, et al. The Association between Influenza and Pneumococcal Vaccinations
424 and SARS-Cov-2 Infection: Data from the EPICOV19 Web-Based Survey. *Vaccines (Basel)*.
425 2020;8(3):E471.
- 426 16. http://www.salute.gov.it/imgs/C_17_pubblicazioni_2571_allegato.pdf accessed 23/09/2020
- 427 17. [http://www.salute.gov.it/portale/influenza/dettaglioContenutiInfluenza.jsp?lingua=italiano&id=679&area=](http://www.salute.gov.it/portale/influenza/dettaglioContenutiInfluenza.jsp?lingua=italiano&id=679&area=influenza&menu=vuoto)
428 [influenza&menu=vuoto](http://www.salute.gov.it/portale/influenza/dettaglioContenutiInfluenza.jsp?lingua=italiano&id=679&area=influenza&menu=vuoto) accessed 23/09/2020
- 429 18. https://www.epicentro.iss.it/vaccini/dati_Ita#flu accessed 23/09/2020
- 430 19. Solomon DA, Sherman AC, Kanjilal S. Influenza in the COVID-19 Era. *JAMA*. Published online August 14,
431 2020. doi:10.1001/jama.2020.14661
- 432 20. <https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2020&codLeg=74451&parte=1%20&serie=null>
433 Accessed 23/9/2020
- 434 21. Zanettini C, Omar M, Dinalankara W, et al. Influenza Vaccination and COVID19 Mortality in the USA.
435 Preprint. *medRxiv*. 2020;2020.06.24.20129817. Published 2020 Jun 26. doi:10.1101/2020.06.24.20129817
- 436 22. Fink, G.; Orlova-Fink, N.; Schindler, T.; Grisi, S.; Ferrer, A.P.; Daubenberger, C.; Brentani, A. Inactivated
437 trivalent influenza vaccine is associated with lower mortality among Covid-19 patients in
438 Brazil. *medRxiv* 2020.06.29.20142505; doi: <https://doi.org/10.1101/2020.06.29.20142505>
- 439 23. Amato M, Werba JP, Frigerio B, et al. Relationship between Influenza Vaccination Coverage Rate and
440 COVID-19 Outbreak: An Italian Ecological Study. *Vaccines (Basel)*. 2020;8(3):E535.

- 441 24. Schmid P, Rauber D, Betsch C, Lidolt G, Denker ML. Barriers of Influenza Vaccination Intention and
442 Behavior - A Systematic Review of Influenza Vaccine Hesitancy, 2005 - 2016. *PLoS One*.
443 2017;12(1):e0170550. Published 2017 Jan 26. doi:10.1371/journal.pone.0170550
- 444 25. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to
445 COVID-19 in Italy. *JAMA*. 2020;323(18):1775–1776. doi:10.1001/jama.2020.4683
- 446 26. Larson HJ, Jarrett C, Eckersberger E, Smith DM, Paterson P. Understanding vaccine hesitancy around
447 vaccines and vaccination from a global perspective: a systematic review of published literature,
448 2007-2012. *Vaccine*. 2014;32(19):2150-2159.
- 449 27. Doherty TM, Del Giudice G, Maggi S. Adult vaccination as part of a healthy lifestyle: moving from
450 medical intervention to health promotion. *Ann Med*. 2019;51(2):128-140.
- 451 28. Genovese C, Picerno IAM, Trimarchi G, et al. Vaccination coverage in healthcare workers: a multicenter
452 cross-sectional study in Italy. *J Prev Med Hyg*. 2019;60(1):E12-E17.
- 453 29. Alicino C, Iudici R, Barberis I, et al. Influenza vaccination among healthcare workers in
454 Italy. *Hum Vaccin Immunother* 2015;11(1):95-100.
- 455 30. Abrams HR, Loomer L, Gandhi A, Grabowski DC. Characteristics of U.S. Nursing Homes with COVID-19
456 Cases. *J Am Geriatr Soc*. 2020 Aug;68(8):1653-1656.
- 457 31. Roxby AC, Greninger AL, Hatfield KM, et al. Outbreak Investigation of COVID-19 Among Residents and
458 Staff of an Independent and Assisted Living Community for Older Adults in Seattle, Washington. *JAMA*
459 *Intern Med*. 2020;180(8):1101-1105.
- 460 32. Nanda A, Vura NVRK, Gravenstein S. COVID-19 in older adults. *Aging Clin Exp Res*. 2020
461 Jul;32(7):1199-1202. doi: 10.1007/s40520-020-01581-5. Epub 2020 May 10. PMID: 32390064; PMCID:
462 PMC7211267

463

Characteristic	Odds Ratio (95% CI)
Sex	
Males	ref
Females not pregnant	0,83 [0,81-0,85]
Females pregnant	1,39 [1,27-1,52]
Age	
Age ≥ 65 yrs	3,06 [2,92-3,20]
Educational level	
Low educational level	ref
Middle educational level	0,98 [0,93-1,03]
High educational level	1,34 [1,28-1,41]
Occupational status	
Employed	ref
Student	0,91 [0,86-0,96]
Unemployed	0,80 [0,75-0,85]
Retired	2,11 [2,01-2,21]
Other	1,26 [1,20-1,33]
Morbidities or clinical conditions	
Lung diseases	1,92 [1,84-2,01]
Heart disease	1,97 [1,86-2,09]
Metabolic disorders	1,60 [1,52-1,68]
Renal diseases	1,30 [1,16-1,46]
Oncological diseases	1,53 [1,44-1,62]
Diseases of the immune system	1,16 [1,12-1,21]
Liver diseases	1,03 [0,91-1,17]
Surgical procedures	1,10 [1,04-1,17]
Work categories recommended for flu vaccine	
No recommendation	ref
Agricultural, forestry and fishery workers	0,85 [0,70-1,03]
Armed forces	
Health professionals	2,79 [2,68-2,90]
Other conditions for recommending flu vaccine	
Residents in nursing home	1,26 [0,95-1,67]
Presence of persons at risk in the household	1,41 [1,37-1,45]
Not self-sufficient in carrying out daily activities	1,29 [1,08-1,53]
Self-perceived health status	
Good	ref
Adequate	1,22 [1,18-1,26]
Bad	1,33 [1,19-1,49]

A



B

